PARIS (Reuters) – French President Emmanuel Macron will on Thursday inaugurate a 2.1 billion euro ($2.3 billion) investment by Danish pharmaceutical company Novo Nordisk in France, his office said, pitching …
nordisk
-
-
(Reuters) – Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The Danish drugmaker …
-
By Maggie Fick and Bhanvi Satija (Reuters) – Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years – limited …
-
By Blake Brittain WASHINGTON (Reuters) – A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss …
-
By Maggie Fick LONDON (Reuters) – Europe will lose out to countries like the U.S. and Japan on new medical research, trials and treatments unless draft rules reforming the European …
-
By Ludwig Burger (Reuters) – Danish drugmaker Novo Nordisk raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit. In a statement on …
-
By Nikolaj Skydsgaard COPENHAGEN – Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy on Thursday, saying there was nothing unusual about a slight delay …